In this issue:
Enzalutamide and PSA levels in metastatic prostate cancer
Treatment patterns and survival in de novo mHSPC
Metastasis-directed therapy vs nodal radiotherapy for oligorecurrent nodal metastases
Radiological PFS as a surrogate for OS in mHSPC
Cardiovascular disease risk with degarelix
Cancer-specific mortality after radical prostatectomy vs radiotherapy
Heterogeneity of PARP inhibitor effects in mCRPC
Long-term outcomes of residual cancer burden after intensified neoadjuvant therapy
Clinical outcomes with ipatasertib and abiraterone
Outcome of subsequent therapies after Lu-PSMA for mCRPC
Please login below to download this issue (PDF)